Cargando…

Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

Tamoxifen is the most commonly prescribed therapy for patients with estrogen receptor (ER)α-positive breast tumors. Tumor resistance to tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress human epidermal growth factor receptor 2 (HER2). Current precl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cittelly, Diana M., Das, Partha M., Salvo, Virgilio A., Fonseca, Juan P., Burow, Matthew E., Jones, Frank E.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994280/ https://www.ncbi.nlm.nih.gov/pubmed/20876285 http://dx.doi.org/10.1093/carcin/bgq192

Ejemplares similares

MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2Δ16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance
por: Huynh, Felicia C., et al.
Publicado: (2014)

Deregulation of ribosomal proteins in human cancers
por: El Khoury, Wendy, et al.
Publicado: (2021)

HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer
por: Hart, Vic, et al.
Publicado: (2021)

MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
por: Ying, Carol Y., et al.
Publicado: (2013)

The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
por: Marchini, Cristina, et al.
Publicado: (2011)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

HPV16 E5 deregulates the autophagic process in human keratinocytes
por: Belleudi, Francesca, et al.
Publicado: (2015)

Deregulation of the miR-16-KRAS axis promotes colorectal cancer
por: You, Chaoying, et al.
Publicado: (2016)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

CircRNA circPDSS1 promotes bladder cancer by down-regulating miR-16
por: Yu, Qinnan, et al.
Publicado: (2020)

miR-4454 up-regulated by HPV16 E6/E7 promotes invasion and migration by targeting ABHD2/NUDT21 in cervical cancer
por: Wang, Hui, et al.
Publicado: (2020)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Methylation of Cervical Neoplastic Cells Infected With Human Papillomavirus 16
por: Ki, Eun Young, et al.
Publicado: (2016)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

miR‐140‐3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2
por: Liu, Dingsheng, et al.
Publicado: (2021)

PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas
por: Klein, Christian H., et al.
Publicado: (2018)

The exon junction complex core factor eIF4A3 is a key regulator of HPV16 gene expression
por: Meznad, Koceila, et al.
Publicado: (2021)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Haploinsufficiency of BCL11A associated with cerebellar abnormalities in 2p15p16.1 deletion syndrome
por: Shimbo, Hiroko, et al.
Publicado: (2017)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment
por: Turpin, Jason, et al.
Publicado: (2016)

Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia
por: Windisch, Roland, et al.
Publicado: (2019)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

Deregulation of apoptosis mediators' p53 and bcl2 in lung tissue of COPD patients
por: Siganaki, Marianna, et al.
Publicado: (2010)

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Author Correction: Deregulation of the miR-16-KRAS axis promotes colorectal cancer
por: You, Chaoying, et al.
Publicado: (2021)

Claspin haploinsufficiency leads to defects in fertility, hyperplasia and an increased oncogenic potential
por: Madgwick, Suzanne, et al.
Publicado: (2022)

LINC00657/miR-26a-5p/CKS2 ceRNA network promotes the growth of esophageal cancer cells via the MDM2/p53/Bcl2/Bax pathway
por: Zhang, Xiao-Mei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9u4527jta8pb4ofuseqhn4f43c